Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence
- PMID: 33530322
- PMCID: PMC7911709
- DOI: 10.3390/v13020180
Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence
Abstract
Hepatitis B Virus (HBV) is a globally-distributed pathogen and is a major cause of liver disease. HBV (or closely-related animal hepadnaviruses) can integrate into the host genome, but (unlike retroviruses) this integrated form is replication-defective. The specific role(s) of the integrated HBV DNA has been a long-standing topic of debate. Novel in vitro models of HBV infection combined with sensitive molecular assays now enable researchers to investigate this under-characterised phenomenon with greater ease and precision. This review covers the contributions these systems have made to understanding how HBV DNA integration induces liver cancer and facilitates viral persistence. We summarise the current findings into a working model of chronic HBV infection and discuss the clinical implications of this hypothetical framework on the upcoming therapeutic strategies used to curb HBV-associated pathogenesis.
Keywords: HBV DNA integration; HBV double-stranded linear DNA; hepatitis B virus; hepatocellular carcinoma (HCC); microhomology-mediated end joining; non-homologous end joining; viral persistence.
Conflict of interest statement
Stephan Urban is co-applicant and co-inventor on patents protecting HBV preS-derived lipopeptides (Myrcludex B) for the use as HBV/HDV entry inhibitors. The other authors in this study declare no competing interests. The funders had no role in the interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures
References
-
- World Health Organization . Global Hepatitis Report 2017. WHO; Geneva, Switzerland: 2017.
-
- Mutz P., Metz P., Lempp F.A., Bender S., Qu B., Schöneweis K., Seitz S., Tu T., Restuccia A., Frankish J., et al. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology. 2018;154:1791–1804. doi: 10.1053/j.gastro.2018.01.044. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
